Madrigal Pharmaceuticals Inc Total Assets
Madrigal Pharmaceuticals Inc total assets. Based on the latest financial reports, Madrigal Pharmaceuticals Inc (MDGL) holds total assets worth $1.26 Billion USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MDGL market cap overview for the company's overall valuation and market capitalisation.
Total Assets of Madrigal Pharmaceuticals Inc (2001–2025)
Total assets of Madrigal Pharmaceuticals Inc from 2001 to 2025. This chart illustrates how Madrigal Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. See latest Madrigal Pharmaceuticals Inc stock price today for real-time trading data and today's change.
Madrigal Pharmaceuticals Inc - Asset Composition Analysis
Madrigal Pharmaceuticals Inc Total Assets Breakdown (December 2025)
Madrigal Pharmaceuticals Inc total assets breakdown as of December 2025. Madrigal Pharmaceuticals Inc's total assets of $1.26 Billion consist of 98.9% current assets and 1.1% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 15.8% |
| Accounts Receivable | $134.48 Million | 10.7% |
| Inventory | $74.84 Million | 5.9% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $7.38 Million | 0.6% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Madrigal Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Madrigal Pharmaceuticals Inc current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Madrigal Pharmaceuticals Inc's current assets represent 98.9% of total assets in 2025, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 15.8% of total assets in 2025, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 10.7% of total assets.
Madrigal Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Madrigal Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Madrigal Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.01 | 6.10 | 6.31 |
| Quick Ratio | 3.77 | 5.90 | 6.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $935.48 Million | $863.65 Million | $259.25 Million |
Madrigal Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Madrigal Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 20.82 |
| Latest Market Cap to Assets Ratio | 9.45 |
| Asset Growth Rate (YoY) | 20.9% |
| Total Assets | $1.26 Billion |
| Market Capitalization | $11.90 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Madrigal Pharmaceuticals Inc's assets at a significant premium (9.45x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Madrigal Pharmaceuticals Inc's assets grew by 20.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Madrigal Pharmaceuticals Inc (2001–2025)
The table below shows the annual total assets of Madrigal Pharmaceuticals Inc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $1.26 Billion | +20.85% |
| 2024-12-31 | $1.04 Billion | +62.71% |
| 2023-12-31 | $640.55 Million | +76.67% |
| 2022-12-31 | $362.57 Million | +32.65% |
| 2021-12-31 | $273.33 Million | -4.76% |
| 2020-12-31 | $287.00 Million | -35.08% |
| 2019-12-31 | $442.06 Million | -8.93% |
| 2018-12-31 | $485.43 Million | +152.42% |
| 2017-12-31 | $192.31 Million | +366.67% |
| 2016-12-31 | $41.21 Million | -39.57% |
| 2015-12-31 | $68.19 Million | -32.26% |
| 2014-12-31 | $100.67 Million | +5.75% |
| 2013-12-31 | $95.20 Million | -7.59% |
| 2012-12-31 | $103.02 Million | +143.40% |
| 2011-12-31 | $42.32 Million | -21.72% |
| 2010-12-31 | $54.07 Million | +10.54% |
| 2009-12-31 | $48.91 Million | -49.71% |
| 2008-12-31 | $97.25 Million | -20.71% |
| 2007-12-31 | $122.65 Million | +123.86% |
| 2006-12-31 | $54.79 Million | -23.06% |
| 2005-12-31 | $71.21 Million | -46.06% |
| 2004-12-31 | $132.02 Million | +64.23% |
| 2003-12-31 | $80.39 Million | +2798.92% |
| 2001-12-31 | $2.77 Million | -- |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.